EVALUATION OF PATIENTS TREATED WITH MOLNUPIRAVIR FOR COVID-19 INFECTION

Abstract

ABSTRACT Purpose:The aim of this study was to evaluate the effect of molnupiravir on the course of the disease in patients hospitalized and followed up in our hospital with a diagnosis of COVID-19. Materials and methods:In this retrospective and observational design study, 78 patients hospitalized with a diagnosis of COVID-19 between 01.11.2021 and 01.05.2022 were evaluated. The data of patients who were suitable for molnupiravir treatment and were given treatment and those who had similar characteristics but were not given treatment were compared. Sociodemographic data of the patients such as age, gender, underlying diseases, oxygen saturations, lung involvement rates in thorax computed tomography, steroid treatment status, follow-up and treatment results were examined. Results: Molnupiravir treatment was given to 39 of the 78 patients included in the study, and no significant difference was detected between the groups in terms of discharge and mortality rates (p = 1). The data of geriatric and non-geriatric patients were also compared, and no difference was found between the two groups in terms of mortality, gender, presence of concomitant chronic disease, CT involvement, and effectiveness of molnupiravir treatment (p>0.05). Conclusion: In our study, no positive or negative effects of MLP treatment on hospital discharge and mortality were shown in hospitalized patients. Keywords: COVID-19, Molnupiravir, Antiviral

Keywords

• COVID-19
• Molnupiravir
• Antiviral

COVID-19 ENFEKSİYONUNDA MOLNUPiRAVİR TEDAVİSİ ALAN HASTALARIN DEĞERLENDİRİLMESİ

Öz

Özet Amaç: Bu araştırmada COVID-19 tanısıyla hastanemizde yatırılarak takip edilen hastalarda molnupiravirin hastalık seyri üzerindeki etkisinin değerlendirilmesi amaçlanmıştır. Gereç ve yöntem: Retrospektif ve gözlemsel tasarımda olan bu çalışmada 01.11.2021-01.05.2022 tarihleri arasında COVID-19 tanısıyla hastanede yatan 78 hasta değerlendirilmiştir. Molnupiravir tedavisi için uygun olup tedavi verilen ve benzer özelliklerde olup tedavi verilmeyen hastaların verileri karşılaştırılmıştır. Hastaların yaş, cinsiyet, komorbid hastalıkları gibi sosyodemografik verileri, oksijen saturasyonları, toraks bilgisayarlı tomografideki akciğer tutulum oranları, steroid tedavisi alma durumları,takip ve tedavi sonuçları incelenmiştir. Bulgular: Çalışmaya alınan 78 hastanın 39’una molnupiravir tedavisi verilmiş olup, taburculuk ve mortalite oranı arasında gruplar arasında anlamlı fark saptanmamıştır (p=1). Geriatrik ve geriatrik olmayan hastaların verileri ayrıca karşılaştırılmış iki grup arasında mortalite ile cinsiyet, eşlik eden kronik hastalık varlığı, BT tutulumu, molnupiravir tedavisinin etkinliği açısından fark bulunmamıştır (p>0.05). Sonuçlar: Çalışmamızda hastaneye yatarak takip edilen hastalarda MLP tedavisinin hastaneden taburculuk ve mortalite üzerinde olumlu veya olumsuz etkisi gösterilmemiştir. Anahtar kelimeler: COVID-19, Molnupiravir, Antiviral

Anahtar Kelimeler

• COVID-19
• molnupiravir
• antiviral

Kaynakça

1. 1. https://www.uptodate.com/contents/covid-19-epidemiology-clinical-features-and-prognosis-of-the-critically-ill-adult )
2. 2. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China [published correction appears in Lancet. 2020 Jan 30;:]. Lancet. 2020;395(10223):497-506.
3. 3. Fischer WA, Eron JJ Jr, Holman W, Cohen MS, Fang L, Szewczyk LJ, Sheahan TP, Baric R, Mollan KR, Wolfe CR, Duke ER, Azizad MM, Borroto-Esoda K, Wohl DA, Coombs RW, James Loftis A, Alabanza P, Lipansky F, Painter WP. A phase 2a clinical trial of molnupiravir in patients with COVID-19 shows accelerated SARS-CoV-2 RNA clearance and elimination of infectious virus. Sci Transl Med. 2022 19;14(628):eabl7430. doi: 10.1126/scitranslmed.abl7430. Epub 2022 Jan 19. PMID: 34941423.
4. 4. https://www.covid19treatmentguidelines.nih.gov/therapies/antivirals-including-antibody-products/molnupiravir/ April 20, 2023
5. 5. T.C. Sağlık Bakanlığı COVID-19 (SARS-CoV-2 Enfeksiyonu) Erişkin Hasta Tedavisi, 12 Şubat 2022, Ankara
6. 6. Fischer WA., et al. A phase 2a clinical trial of molnupiravir in patients with COVID-19 shows accelerated SARS-CoV-2 RNA clearance and elimination of infectious virus. Science translational medicine, 2021, 14.628: eabl7430
7. 7. Jayk Bernal A, Gomes da Silva MM, Musungaie DB, et al. Molnupiravir for oral treatment of covıd-19 in nonhospitalized patients. N Engl J Med . 2022;386(6):509-520. https://www.ncbi.nlm.nih.gov/pubmed/34914868
8. 8. Johnson MG, Puenpatom A, Moncada PA, et al. Effect of molnupiravir on biomarkers, respiratory interventions, and medical services in COVID-19: a randomized, placebo-controlled trial. Ann Intern Med. 2022;175(8):1126-1134.

9. 9. Efficacy and safety of molnupiravir (MK-4482) in hospitalized adult participants with COVID-19 (MK-4482-001) - full text view - ClinicalTrials.gov. (Last accessed on October 20, 2021)
10. 10. Butler CC, Hobbs FDR, Gbinigie OA et al. Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label, platform-adaptive randomised controlled trial. Lancet. 2023; 401: 281-293
11. 11. Serdar, E. K., İLHANLI, H., & Kahraman, S. Ö. (2020). COVID-19’un zayıf halkası: Yaşlı nüfus. Türk Coğrafya Dergisi, (76), 33-44.
12. 12. Hotar, N., Omay, R. E., Bayrak, S., Kuruüzüm, Z., & Ünal, B. (2020). Pandeminin toplumsal yansımaları. İzmir İktisat Dergisi, 35(2), 211-220. https://doi.org/10.24988/ije.202035201
13. 13. Soysal, G. (2020). Koronavirüs salgını ve yaşlılık. Avrasya Sosyal ve Ekonomi Araştırmaları Dergisi, 7(5), 290-301. https://dergipark. org.tr/tr/pub/asead/issue/54658/736807
14. 14. Senderovich H, Vinoraj D, Stever M, Waicus S. Efficacy of COVID-19 treatments among geriatric patients: a systematic review. Ther Adv Infect Dis. 2022; 9:20499361221095666.
15. 15. Tsai YW, Wu JY, Liu TH, et al. Clinical effectiveness of oral antiviral agents in older patients with COVID-19 based on real-world data. J Med Virol. 2023;95(6):e28869.